Hair Loss Medication Interactions: What to Tell Your Surgeon

The 7-Category Disclosure Framework That Separates Safe Candidates From Preventable Complications

Introduction: Why Your Medication List Is as Important as Your Donor Density

Hair transplant surgery is, first and foremost, a surgical procedure. It is performed under local anesthesia, involves controlled bleeding, and depends on careful wound healing for the transplanted grafts to survive and thrive. That means every medication a patient takes, not just their hair loss drugs, has the potential to affect safety, bleeding, healing, and the ultimate quality of the result.

This matters more today than ever before. According to the ISHRS 2025 Practice Census, 95% of first-time hair restoration patients in 2024 were aged 20 to 35. This is precisely the demographic most likely to be taking antidepressants, stimulants for ADHD, hormonal therapies, and a range of supplements alongside their finasteride or minoxidil. The result is a polypharmacy picture that a simple “stop or continue your hair meds” checklist cannot address.

The stakes are real. Incomplete medication disclosure is not merely a paperwork oversight; it creates preventable surgical complications. Per formal hair transplant practice guidelines, preoperative documentation is also admissible as documentary evidence in legal proceedings, which underscores why meticulous disclosure protects both patient and practice.

This article introduces the 7-Category Disclosure Framework, structured the way a physician-surgeon conducts a thorough intake conversation during a genuine consultation. It goes well beyond finasteride and minoxidil to cover SSRIs, JAK inhibitors, oral minoxidil, anticoagulant bridging therapy, herbal supplements, and chronic disease medications. Disclosing a medication almost never disqualifies a patient; it simply enables the surgeon to individualize risk assessment, exactly as the ISHRS recommends.

Understanding the Framework: How Surgeons Categorize Medication Risk

Not all medications pose the same type of risk. Surgeons think in categories: bleeding and hemostasis, wound healing, immune response, anesthesia interaction, and hormonal or DHT-pathway effects.

The critical clinical distinction that underpins the entire framework is this: some medications must be stopped before surgery (NSAIDs, topical minoxidil, anticoagulants, and many herbal supplements), while others must be continued (antihypertensives and antiandrogenic therapies like finasteride, dutasteride, and spironolactone). Stopping the wrong drug can be just as dangerous as continuing the wrong one.

The ISHRS is explicit that bleeding risk assessment “must be individualized to the patient.” A complete medication picture is what makes that individualization possible. The seven categories explored in this article are:

1. Hair loss medications
2. Anticoagulants and antiplatelets
3. Antidepressants and psychiatric medications
4. JAK inhibitors and immunomodulatory agents
5. Chronic disease medications
6. Herbal supplements, vitamins, and over-the-counter products
7. Lifestyle factors with pharmacological impact

Category 1: Hair Loss Medications — The Ones Patients Assume Their Surgeon Already Knows About

Finasteride and minoxidil represent the most common medication interaction scenario. The ISHRS 2025 Practice Census reports that 72.3% of surgeons prescribe finasteride to their male patients before and after a hair transplant, so this conversation is entirely routine.

Finasteride and dutasteride (5-alpha reductase inhibitors) should not be stopped before or after surgery. They do not impact bleeding or wound healing, and stopping them risks accelerated DHT-driven hair loss post-operatively, per the 2023 international expert consensus.

Spironolactone and bicalutamide, antiandrogenic therapies used in female pattern hair loss, follow the same guidance: do not stop, as they do not affect hemostasis.

Topical minoxidil (2% to 5%) should be stopped 7 days before surgery to minimize scalp irritation and reduce the potential risk of increased intraoperative bleeding.

Oral minoxidil (off-label, low-dose) is a growing and clinically underreported scenario. Because it increases blood flow to the scalp, it can raise bleeding risk and prolong healing. Some clinics recommend stopping it 2 to 3 weeks before surgery. Patients must clearly disclose whether they take the topical or oral form.

A CYP interaction alert applies to dutasteride users: dutasteride’s pharmacokinetics can be significantly altered by azole antifungal drugs such as ketoconazole, a CYP3A inhibitor. Patients on both must flag this combination.

Hormonal contraceptives should also be disclosed, as they are antiandrogenic and part of the hormonal picture for female patients.

Category 2: Anticoagulants and Antiplatelets — The Bridging Therapy Conversation

This category demands the most careful individualized management, because anticoagulants prevent the very clotting essential for surgical hemostasis and healing.

NSAIDs (ibuprofen, naproxen, aspirin) must be discontinued at least 7 to 10 days before surgery due to blood-thinning properties that raise bleeding risk.

Warfarin requires that INR typically fall below 1.5 for safe surgery. Some patients may need bridging therapy, switching to short-acting injectable low-molecular-weight heparin (LMWH) before the procedure. Stopping warfarin for more than 4 to 5 days pre-operatively carries its own thromboembolic risks.

Direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and dabigatran should, per the 2023 international expert consensus, be stopped 72 to 96 hours before hair transplantation, but only after approval from the patient’s primary care physician or specialist.

Antiplatelet agents like clopidogrel (Plavix) should be disclosed immediately as potential contraindications. Cessation decisions must involve the prescribing cardiologist or internist.

One rule is non-negotiable: the hair restoration surgeon does not unilaterally decide to stop anticoagulants. This is a coordinated decision with the prescribing physician. Being on anticoagulants does not automatically disqualify a patient; it requires a coordinated pre-surgical plan, not avoidance of disclosure.

Category 3: Antidepressants and Psychiatric Medications — The Most Underreported Surgical Risk

This category is clinically underreported for two reasons: patients often do not connect an antidepressant to surgical risk, and many feel stigma around disclosing psychiatric medications.

SSRIs (fluoxetine, sertraline, paroxetine, escitalopram) adversely affect hemostasis by limiting serotonin reuptake crucial for platelet aggregation. A systematic review in plastic surgery found post-operative bleeding rates of 1.9% to 2.6% and a 4.14-fold increase in hematoma reoperation risk in some procedures.

Critically, SSRIs must not be abruptly discontinued before surgery. Doing so risks SSRI discontinuation syndrome, which can be severe. The surgeon needs to be informed so that anesthesia and post-operative protocols can be adjusted accordingly.

There is also a CYP enzyme interaction to consider: fluoxetine and paroxetine are potent CYP2D6 inhibitors, creating clinically significant interactions with post-operative analgesics like codeine and tramadol, which rely on the same enzyme.

SNRIs (venlafaxine, duloxetine) carry similar hemostatic and anesthesia considerations. MAOIs and TCAs add hemodynamic and anesthesia interaction risks. Stimulants (Adderall, Ritalin) affect cardiovascular response and may interact with local anesthetics. Antipsychotics and mood stabilizers can affect hemodynamic stability. The rule is straightforward: disclose all psychiatric medications without exception.

Category 4: JAK Inhibitors and Immunomodulatory Agents — The Emerging Frontier

JAK inhibitors (baricitinib, ruxolitinib, tofacitinib) are now first-line treatment for severe alopecia areata, with baricitinib receiving FDA approval in June 2022. A growing population of hair loss patients is now on these agents.

The surgical relevance is significant: JAK inhibitors suppress certain immune pathways, which has implications for wound healing, infection risk, and graft survival. Patients on them must disclose their use, and any decision to continue, pause, or modify dosing requires coordination between the surgeon and the prescribing dermatologist or rheumatologist.

Biologics used for scarring alopecias or inflammatory conditions carry similar immune-modulating considerations. Corticosteroids (oral or injectable) adversely affect wound healing and graft survival with chronic use. Immunosuppressants such as methotrexate and cyclosporine impair immune response and healing. All require full disclosure.

It is also worth noting that patients on JAK inhibitors may have alopecia areata rather than androgenetic alopecia, and the underlying diagnosis affects candidacy for hair transplant surgery independently of the medication itself.

Category 5: Chronic Disease Medications — The Category Most Patients Forget to Mention

Many patients assume their blood pressure medication has nothing to do with a hair transplant. That assumption is incorrect.

Antihypertensives (beta-blockers, ACE inhibitors, calcium channel blockers) should generally be continued through surgery. Abrupt cessation can cause dangerous rebound hypertension. Beta-blockers specifically can mask tachycardia, a sign of epinephrine absorption from local anesthetic, making surgical-team awareness essential.

Insulin and diabetes medications matter because diabetes affects wound healing and graft survival. Blood glucose management on the day of surgery requires specific guidance from the surgeon.

Thyroid medications (levothyroxine, methimazole) matter because thyroid dysfunction affects hair cycling and healing, helping the surgeon contextualize the hair loss pattern.

Statins generally continue but should be disclosed, as some carry mild platelet effects. Diuretics can affect electrolyte balance and hydration status on the day of surgery.

The overarching message is consistent: every prescription medication for every chronic condition belongs on the disclosure list. The surgeon determines relevance, not the patient.

Category 6: Herbal Supplements, Vitamins, and Over-the-Counter Products — The Hidden Bleeding Risk

Patients frequently omit supplements because they do not consider them medications. That omission carries real risk.

Blood-thinning supplements that should be stopped 1 to 2 weeks before surgery include vitamin E, fish oil and omega-3s, garlic, ginkgo biloba, ginseng, green tea extract, saw palmetto, St. John’s Wort, danshen, feverfew, and flaxseed.

Per ISHRS guidance, vitamin E specifically should be stopped 2 to 3 weeks prior due to its documented effect on bleeding risk. B vitamins and multivitamins containing B or E should be stopped 1 week before surgery.

St. John’s Wort carries a dual risk: mild anticoagulant properties, plus CYP enzyme induction that can alter anesthetic and analgesic metabolism. Kava is associated with cardiovascular instability and hepatotoxicity. Saw palmetto has both antiandrogenic and mild anticoagulant properties, making it relevant as both a hair supplement and a surgical risk factor.

The ISHRS recommends patients create a full checklist of all drugs, medications, vitamins, and supplements, including products purchased without a prescription. “Natural” does not mean “safe” in a surgical context; these pharmacodynamic mechanisms are well documented in peer-reviewed literature.

Category 7: Lifestyle Factors With Pharmacological Impact — Alcohol, Smoking, and Recreational Substances

Lifestyle factors with pharmacological effects belong in the disclosure conversation alongside medications.

Alcohol acts as a vasodilator and blood thinner and should be avoided for at least 3 days before surgery. Chronic use affects liver function, which in turn affects drug metabolism and coagulation.

Smoking should be stopped 3 to 6 weeks before surgery and for the same duration afterward. Nicotine and carbon monoxide inhibit blood flow, impair wound healing, and significantly reduce graft survival.

Recreational substances carry distinct risks: smoked cannabis affects pulmonary function and anesthetic interaction; stimulants like cocaine and MDMA pose serious cardiovascular risks in a surgical setting; opioids complicate pain management planning. Vaping and nicotine replacement products carry vasoconstrictive effects similar to smoking.

This is a judgment-free clinical conversation. The surgeon’s goal is patient safety, not moral evaluation. Patients who smoke or drink heavily are not automatically disqualified; they may be candidates after an appropriate cessation period the surgeon will advise.

How to Prepare a Surgeon-Ready Medication Disclosure Before the Consultation

Building a complete disclosure document in advance makes any consultation more productive.

• Step 1: Compile a complete list. Include every prescription medication (with dose and frequency), every over-the-counter medication, every vitamin and supplement, and every herbal product. Do not pre-filter based on assumed relevance.
• Step 2: Note the indication. Knowing why a patient takes a medication helps the surgeon understand the underlying condition.
• Step 3: Flag recent changes. Anything started, stopped, or dose-adjusted in the past 3 to 6 months is particularly relevant.
• Step 4: Include prescribing physicians’ contact information. For anticoagulants, immunosuppressants, and psychiatric medications, coordination may be required.
• Step 5: Disclose drug allergies and adverse reactions. This is a distinct and essential category.

The ISHRS 2025 Census reports that 72% of prospective patients now request a virtual consultation before committing to a provider. A complete medication list prepared in advance makes those virtual consultations clinically meaningful. Patients should never omit medical history or medications out of fear of disqualification; incomplete information leads to incomplete and potentially unsafe surgical assessments.

What Happens During the Medication Review at a Physician-Led Consultation

There is a meaningful difference between a physician-surgeon-led consultation and a sales-coordinator-led one. Medication review is a clinical dialogue that requires medical training to conduct safely.

A thorough intake covers all seven categories: assessing bleeding risk, evaluating wound-healing factors, identifying anesthesia interactions, and building a coordination plan for medications requiring specialist input. From this, the surgeon constructs an individualized pre-operative protocol, which may include adjusted cessation timelines, bridging therapy coordination, modified anesthesia protocols, or specialist consultation as needed.

The medication picture also shapes recovery. Graft survival, infection risk, and healing are all influenced by a patient’s ongoing regimen. At Charles Medical Group, Dr. Charles personally conducts consultations and reviews each patient’s complete medical picture. This physician-led approach enables the individualized risk assessment the ISHRS recommends, with the goal of finding a safe path to surgery rather than reasons to decline.

The 7-Category Framework at a Glance: A Pre-Consultation Reference

• Category 1, Hair Loss Medications: Disclose all. Topical minoxidil: stop 7 days pre-op. Oral minoxidil: stop 2 to 3 weeks pre-op. Finasteride, dutasteride, spironolactone, and bicalutamide: continue.
• Category 2, Anticoagulants and Antiplatelets: Disclose all. NSAIDs: stop 7 to 10 days pre-op. Warfarin and DOACs: stop 72 to 96 hours pre-op with prescribing physician approval. Bridging therapy may be required.
• Category 3, Antidepressants and Psychiatric Medications: Disclose all. Do not abruptly stop SSRIs; the surgeon adjusts anesthesia and analgesic protocols accordingly.
• Category 4, JAK Inhibitors and Immunomodulatory Agents: Disclose all. Continuation or cessation requires specialist coordination.
• Category 5, Chronic Disease Medications: Disclose all. Most continue through surgery; the surgeon determines each protocol.
• Category 6, Herbal Supplements and Vitamins: Disclose all. Most blood-thinning supplements: stop 1 to 2 weeks pre-op. Vitamin E: stop 2 to 3 weeks pre-op.
• Category 7, Lifestyle Factors: Alcohol: stop 3 days pre-op. Smoking: stop 3 to 6 weeks pre-op and post-op. Disclose all recreational substances.

This reference is a starting point. The surgeon’s individualized guidance always supersedes any general timeline.

Conclusion: Complete Disclosure Is the Foundation of a Safe Surgical Outcome

The difference between a safe hair transplant and a preventable complication often comes down to what the patient tells the surgeon before the procedure begins. Hair loss patients, especially the 20-to-35 demographic that now represents 95% of first-time candidates, are frequently on multiple medications across several of the seven categories simultaneously.

The critical distinction remains: some medications must be stopped, some must be continued, and some require specialist coordination. Only complete disclosure lets the surgeon determine which is which. Patients may feel embarrassed, fearful of disqualification, or unsure what is relevant, but the ISHRS is clear that the patient’s role is to provide full information and the surgeon’s role is to individualize the assessment. Thorough medication disclosure is not a barrier to surgery; it is the clinical foundation that makes surgery possible safely.

Ready to Have the Full Conversation? Schedule a Consultation with Dr. Charles

Charles Medical Group’s consultation is where the 7-Category Disclosure Framework comes to life: a physician-led, individualized intake process conducted personally by Dr. Glenn Charles. As Past President of the American Board of Hair Restoration Surgery and author and editor of the field’s most widely recognized textbooks, Hair Transplantation and Hair Transplant 360, Dr. Charles brings the highest clinical standard to every medication review.

Consultations are complimentary and available both in-person at the Boca Raton and Miami locations and virtually via FaceTime or Skype, making it easy to begin the disclosure conversation regardless of location. Patients are encouraged to use the 7-Category Framework from this article to prepare a complete medication list beforehand; arriving prepared makes the dialogue more productive and the surgical plan more precise.

To take the first step, call 866-395-5544 or visit charlesmedicalgroup.com. The goal of the consultation is straightforward: to find the safest path to the outcome the patient is seeking, and complete disclosure is where that path begins.